TY - JOUR
T1 - Prospective cohort study of hospitalized adults with advanced cancer
T2 - Associations between complications, comorbidity, and utilization
AU - May, Peter
AU - Garrido, Melissa M.
AU - Aldridge, Melissa D.
AU - Cassel, J. Brian
AU - Kelley, Amy S.
AU - Meier, Diane E.
AU - Normand, Charles
AU - Penrod, Joan D.
AU - Smith, Thomas J.
AU - Morrison, R. Sean
N1 - Funding Information:
Disclosure: The study was funded by grant R01 CA116227 from the National Cancer Institute and the National Institute of Nursing Research. The study sponsors had no role in design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the US Department of Veterans Affairs or the US government. All authors are independent of the study sponsors. Dr. May was supported by a HRB/ NCI Health Economics Fellowship during this work. Dr. Garrido is supported by a Veterans Affairs HSR&D career development award (CDA 11-201/CDP 12-255). Dr. Kelley’s time was funded by the National Institute on Aging (1K23AG040774-01A1) and the American Federation for Aging. Dr Smith is funded by the NCI Core Grant P 30 006973, 1-R01 CA177562-01A1, 1-R01 NR014050 01, and the Harry J. Duffey Family Endowment for Palliative Care. Dr Morrison was the recipient of a Midcareer Investigator Award in Patient-Oriented Research (5K24AG022345) during the course of this work. This work was supported by the NIA, Claude D.
Funding Information:
The authors thank Robert Arnold, Phil Santa Emma, Mary Beth Happ, Tim Smith, and David Weissman for contributing to the Palliative Care for Cancer (PC4C) project. Disclosure: The study was funded by grant R01 CA116227 from the National Cancer Institute and the National Institute of Nursing Research. The study sponsors had no role in design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the US Department of Veterans Affairs or the US government. All authors are independent of the study sponsors. Dr. May was supported by a HRB/ NCI Health Economics Fellowship during this work. Dr. Garrido is supported by a Veterans Affairs HSR&D career development award (CDA11-201/CDP 12-255). Dr. Kelley’s time was funded by the National Institute on Aging (1K23AG04077401A1) and the American Federation for Aging. Dr Smith is funded by the NCI Core Grant P 30 006973, 1-R01 CA177562-01A1, 1-R01 NR014050 01, and the Harry J. Duffey Family Endowment for Palliative Care. Dr Morrison was the recipient of a Midcareer Investigator Award in Patient-Oriented Research (5K24AG022345) during the course of this work. This work was supported by the NIA, Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai [5P30AG028741], and the National Palliative Care Research Center.
Publisher Copyright:
© 2017 Society of Hospital Medicine.
PY - 2017/6
Y1 - 2017/6
N2 - BACKGROUND: Inpatient hospital stays account for more than a third of direct medical cancer care costs. Evidence on factors driving these costs can inform planning of services, as well as consideration of equity in access. OBJECTIVE: To measure the association between hospital costs, and demographic, clinical, and system factors, for a cohort of adults with advanced cancer. DESIGN: Prospective multisite cohort study. SETTING: Four medical and cancer centers. PATIENTS: Adults with advanced cancer admitted to a participating hospital between 2007 and 2011, excluding those with dementia. Final analytic sample included 1020 patients. METHODS: With receipt of palliative care controlled for, the associations between hospital cost and patient factors were estimated. Factors covered the domains of demographics (age, sex, race), socioeconomics and systems (education, insurance, living will, proxy), clinical care (diagnoses, complications deemed to pose a threat to life or bodily functions, comorbidities, symptom burden, activities of daily living), and prior healthcare utilization (home help, analgesic prescribing). OUTCOME MEASURE: Direct hospital costs. RESULTS: A major (markedly abnormal) complication (+$8267; P < 0.01), a minor but not a major complication (+$5289; P < 0.01), and number of comorbidities (+$852; P < 0.01) were associated with higher cost, and admitting diagnosis of electrolyte disorders (–$4759; P = 0.01) and increased age (–$53; P = 0.03) were associated with lower cost. CONCLUSIONS: Complications and comorbidity burden drive inhospital utilization for adults with advanced cancer. There is little evidence of sociodemographic associations and no apparent impact of advance directives. Attempts to control growth of hospital cancer costs require consideration of how the most resource-intensive patients are identified promptly and prioritized for cost-effective care.
AB - BACKGROUND: Inpatient hospital stays account for more than a third of direct medical cancer care costs. Evidence on factors driving these costs can inform planning of services, as well as consideration of equity in access. OBJECTIVE: To measure the association between hospital costs, and demographic, clinical, and system factors, for a cohort of adults with advanced cancer. DESIGN: Prospective multisite cohort study. SETTING: Four medical and cancer centers. PATIENTS: Adults with advanced cancer admitted to a participating hospital between 2007 and 2011, excluding those with dementia. Final analytic sample included 1020 patients. METHODS: With receipt of palliative care controlled for, the associations between hospital cost and patient factors were estimated. Factors covered the domains of demographics (age, sex, race), socioeconomics and systems (education, insurance, living will, proxy), clinical care (diagnoses, complications deemed to pose a threat to life or bodily functions, comorbidities, symptom burden, activities of daily living), and prior healthcare utilization (home help, analgesic prescribing). OUTCOME MEASURE: Direct hospital costs. RESULTS: A major (markedly abnormal) complication (+$8267; P < 0.01), a minor but not a major complication (+$5289; P < 0.01), and number of comorbidities (+$852; P < 0.01) were associated with higher cost, and admitting diagnosis of electrolyte disorders (–$4759; P = 0.01) and increased age (–$53; P = 0.03) were associated with lower cost. CONCLUSIONS: Complications and comorbidity burden drive inhospital utilization for adults with advanced cancer. There is little evidence of sociodemographic associations and no apparent impact of advance directives. Attempts to control growth of hospital cancer costs require consideration of how the most resource-intensive patients are identified promptly and prioritized for cost-effective care.
UR - http://www.scopus.com/inward/record.url?scp=85037824734&partnerID=8YFLogxK
U2 - 10.12788/jhm.2745
DO - 10.12788/jhm.2745
M3 - Article
C2 - 28574529
AN - SCOPUS:85037824734
SN - 1553-5606
VL - 12
SP - 407
EP - 413
JO - Journal of Hospital Medicine
JF - Journal of Hospital Medicine
IS - 6
ER -